Literature DB >> 12631602

p21 expression predicts outcome in p53-null ovarian carcinoma.

Stephen L Rose1, Michael J Goodheart, Barry R DeYoung, Brian J Smith, Richard E Buller.   

Abstract

PURPOSE: p21 is a direct p53 response gene. Although several studies have correlated p21 and p53 expression, only one has evaluated p21 expression as a function of sequenced p53 gene mutation. We hypothesize that such an analysis may be useful in prognosticating outcome for individuals diagnosed with epithelial ovarian cancer. EXPERIMENTAL
DESIGN: DNA from the primary ovarian cancers of 267 patients was studied. p53 mutations were directly sequenced. Two percent or greater nuclear staining with WAF1/CIP1 monoclonal antibody was determined by a hazard ratio analysis to constitute positive p21 expression.
RESULTS: Positive p21 nuclear staining occurred more frequently in p53 wild-type ovarian tumors than tumors found to have a p53 mutation (P = 0.001). Positive p21 staining conferred an overall survival advantage (P = 0.02). p21 expression in cancers with p53 missense mutations was not prognostic but did show a strong trend toward significance in the wild-type p53 subset (P = 0.056). Surprisingly, positive p21 staining reflected compromised survival for individuals with p53-null ovarian cancers (P = 0.005). The mean expression level for p21-positive stains in the wild-type group was greater than in null p53 cancers (23 versus 11%; P = 0.001). A Cox multivariable analysis revealed p21 to be a strong independent prognostic factor in p53-null ovarian cancer (P = 0.02).
CONCLUSION: p21 expression is closely related to sequenced p53 mutations. This is the first study of positive p21 staining as an independent poor prognostic factor in p53-null ovarian cancer. A dual role for p21 activity, dependent on levels of expression, appears to explain these paradoxical results and is consistent with a complex model for regulation of p21.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631602

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

1.  Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.

Authors:  Jane N Winter; Shuli Li; Vikas Aurora; Daina Variakojis; Beverly Nelson; Maryla Krajewska; Lijun Zhang; Thomas M Habermann; Richard I Fisher; William R Macon; Mukesh Chhanabhai; Raymond E Felgar; Eric D Hsi; L Jeffrey Medeiros; James K Weick; Edie A Weller; Ari Melnick; John C Reed; Sandra J Horning; Randy D Gascoyne
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

2.  Using co-occurrence network structure to extract synonymous gene and protein names from MEDLINE abstracts.

Authors:  A M Cohen; W R Hersh; C Dubay; K Spackman
Journal:  BMC Bioinformatics       Date:  2005-04-22       Impact factor: 3.169

3.  Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer.

Authors:  Annette Schmider-Ross; Olaf Pirsig; Elisabeth Gottschalk; Carsten Denkert; Werner Lichtenegger; Angela Reles
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-19       Impact factor: 4.553

Review 4.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

5.  Expression of Smad4, TGF-βRII, and p21waf1 in esophageal squamous cell carcinoma tissue.

Authors:  Hui Cheng; Cheng Chen; L U Liu; N A Zhan; Benhui Li
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

Review 6.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

7.  A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging.

Authors:  Jeng-Feng Chiou; Alexander T H Wu; Wei-Tin Wang; Tsu-Hsiang Kuo; Juri G Gelovani; I-Hsin Lin; Chih-Hsiung Wu; Wen-Ta Chiu; Win-Ping Deng
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-13       Impact factor: 2.629

8.  TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.

Authors:  Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie
Journal:  Int J Oncol       Date:  2014-11-11       Impact factor: 5.650

9.  Splice-acceptor site mutation in p53 gene of hu888 zebrafish line.

Authors:  Alicja Piasecka; Paweł Brzuzan; Maciej Woźny; Sławomir Ciesielski; Dariusz Kaczmarczyk
Journal:  J Appl Genet       Date:  2014-09-03       Impact factor: 3.240

10.  Preoperative transcatheter arterial chemotherapy may suppress oxidative stress in hepatocellular carcinoma cells and reduce the risk of short-term relapse.

Authors:  Hao Su; Guangzhi Zhu; Ketut Indra Djaja P; Yi Lin; Yizhen Gong; Xiaoguang Liu; Jiaquan Li; Zhiming Liu; Xiao Qin; Lequn Li; Tangwei Liu; Zili Lu; Minyi Wei; Lunan Yan; Cheryl Ann Winkler; Stephen J O'Brien; Jing Li; Kaiyin Xiao; Tao Peng
Journal:  Oncotarget       Date:  2017-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.